Amy Elazzouzi sold $52k of AURA
Senior Vice President, Finance at Aura Biosciences, Inc.. 7,722 shares at an average of $6.70, traded Aug 18, 2025, filed Aug 18, 2025.
Score components
- +15RoleOfficer
- +7Trade size$52k at market
- 0Share of holdings soldSold 8.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.8%, 3m -17.8%, 6m -16.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-109767, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2025 | MOption exercise Common Stock | +2,554 | $5.07 | $13k | 83,935 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Common Stock | +1,094 | $5.48 | $5,995 | 85,029 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Common Stock | +547 | $5.48 | $2,998 | 85,576 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Common Stock | +547 | $5.21 | $2,850 | 86,123 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Common Stock | +4,744 | $2.74 | $13k | 90,867 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Common Stock | +1,094 | $3.16 | $3,457 | 91,961 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Common Stock | +2,319 | $4.25 | $9,856 | 94,280 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -7,722 | $6.70 | $52k | 86,558 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -2,554 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -1,094 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -547 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -547 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -4,744 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -1,094 | $0.00 | $0 | 0 | Aug 18, 2025 |
| Aug 18, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -2,319 | $0.00 | $0 | 0 | Aug 18, 2025 |
Related signals
Other insiders at Aura Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | AURAsell Aura Biosciences, Inc. | Anthony S Gibney See Remarks | $82k 12,824 shares | -5% | |
| 57Moderate | AURAsell Aura Biosciences, Inc. | Matrix Capital Management Company, LP owner | $39M 6,922,870 shares | -100% | |
| 24Weak | AURAsell Aura Biosciences, Inc. | Conor Kilroy See Remarks | $82k 11,738 shares | -5% | |
| 48Moderate | Aura Biosciences, Inc. | Pinos Elisabet de los See Remarks | $241k 47,648 shares | -10% | |
| 41Moderate | Aura Biosciences, Inc. | Amy Elazzouzi Senior Vice President, Finance | $43k 8,549 shares | -10% | |
| 40Moderate | Aura Biosciences, Inc. | Janet Jill Hopkins Chief Medical Officer | $103k 20,401 shares | -8% | |
| 39Weak | Aura Biosciences, Inc. | Mark Plavsic Chief Technology Officer | $80k 15,890 shares | -8% | |
| 37Weak | Aura Biosciences, Inc. | Conor Kilroy See Remarks | $61k 12,079 shares | -7% | |
| 32Weak | Aura Biosciences, Inc. | Pinos Elisabet de los See Remarks | $82k 16,928 shares | -4% | |
| 23Weak | Aura Biosciences, Inc. | Amy Elazzouzi Senior Vice President, Finance | $7,684 1,581 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.